XEN D0501

Drug Profile

XEN D0501

Alternative Names: BAY-69-9426; XEND0501

Latest Information Update: 28 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xention
  • Developer Ario Pharma; PILA PHARMA
  • Class Small molecules; Urologics
  • Mechanism of Action TRPV1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Discontinued Cough; Overactive bladder

Most Recent Events

  • 23 Aug 2018 Phase-II clinical trials in Type-2 diabetes mellitus (Adjuvant therapy) in Lithuania (PO) (EudraCT2018-001880-22)
  • 31 Aug 2017 XEN D0501 is available for licensing as of 09 May 2017. http://pilapharma.com/
  • 30 Aug 2017 Pila Pharma plans an efficacy trial for Type-2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top